Stock LFCR LIFECORE BIOMEDICAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Lifecore Biomedical, Inc.

Equities

LFCR

US5147661046

Real-time Estimate Cboe BZX
Other stock markets
 03:04:28 2024-04-29 pm EDT 		5-day change 1st Jan Change
6.42 USD -2.65% Intraday chart for Lifecore Biomedical, Inc. +2.62% +4.28%
Apr. 19 Lifecore Biomedical Gets Nasdaq Warning Over Delayed Quarterly Report MT
Apr. 01 Lifecore Biomedical, Inc. Provides Revenue Guidance for Full Year Fiscal 2024 CI

Strengths

  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 59% by 2026.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For several months, analysts have been revising their EPS estimates roughly upwards.

Weaknesses

  • The company has insufficient levels of profitability.
  • The company is highly valued given the cash flows generated by its activity.
  • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
LIFECORE BIOMEDICAL, INC. Stock Lifecore Biomedical, Inc.
+4.28% 201M
B-
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.74% 566B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.71% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.04% 332B
B-
ABBVIE INC. Stock AbbVie Inc.
+3.27% 283B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.43% 231B
B+
NOVARTIS AG Stock Novartis AG
+4.71% 200B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.53% 195B
A+
AMGEN INC. Stock Amgen Inc.
-4.22% 145B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. LFCR Stock
  4. Ratings Lifecore Biomedical, Inc.